Philadelphia University + Thomas Jefferson University

Stem Cells

This research is based on a new paradigm emerging in oncology; the only truly effective way to prevent or treat cancer is to selectively target cancer stem cells (CSC). This view is supported by mounting evidence that overpopulation of CSC drives tumor initiation & progression and that CSCs are relatively resistant to conventional therapies. Our goal is to identify mechanisms that regulate normal stem cell (SC) population size in tissues, and to determine how dysregulation of these mechanisms leads to stem cell overpopulation and cancer development. Understanding these mechanisms would provide a rationale for development of therapeutics that target and eliminate CSC.

  • Adam Dicker, MD, PhD
    Professor, Chairman and Director, Experimental Radiation Oncology Division
  • Bo Lu, MD, PhD
    Professor, Director, Division of Molecular Radiation Biology
  • Dennis B. Leeper, PhD
    Professor and Founding Director
  • Robert Den, MD
    Assistant Professor
  • Mark Hurwitz, MD
    Professor and Vice-Chair for Quality, Safety, and Performance Excellence
    Director of Thermal Oncology
    Medical Student Education/Clerkship Director
  • Nicole Simone, MD
    Assistant Professor
  • Wenyin Shi, MD
    Assistant Professor
    Medical Director of Radiation Oncology at JHN

Adjunct Faculty

  • Randy Burd, PhD
    Assistant Professor, University of Arizona
  • Yaacov Richard Lawrence, MD
    Director, Center for Translational Research in Radiation Oncology
    Sheba Medical Center, Tel HaShomer Hospital
    Tel Aviv University, Tel Aviv, Israel
  • Languino, Lucia
    Professor, Cancer Biology
  • Zhang, Jianke
    Associate Professor, Microbiology & Immunology
  • Karen Knudsen, PhD 
    Professor, Cancer Biology
  • Ullrich Rodeck, MD
    Professor of Dermatology

In The News

Read More